Share

November 17, 2015; 85 (20) Article

Mediterranean diet and brain structure in a multiethnic elderly cohort

Yian Gu, Adam M. Brickman, Yaakov Stern, Christian G. Habeck, Qolamreza R. Razlighi, José A. Luchsinger, Jennifer J. Manly, Nicole Schupf, Richard Mayeux, Nikolaos Scarmeas
First published October 21, 2015, DOI: https://doi.org/10.1212/WNL.0000000000002121
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1160

Share

Article Information

vol. 85 no. 20 1744-1751
DOI: 
https://doi.org/10.1212/WNL.0000000000002121
PubMed: 
26491085
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received February 27, 2015
  • Accepted in final form July 16, 2015
  • First Published October 21, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Yian Gu, PhD,
    2. Adam M. Brickman, PhD,
    3. Yaakov Stern, PhD,
    4. Christian G. Habeck, PhD,
    5. Qolamreza R. Razlighi, PhD,
    6. José A. Luchsinger, PhD,
    7. Jennifer J. Manly, PhD,
    8. Nicole Schupf, PhD,
    9. Richard Mayeux, MD and
    10. Nikolaos Scarmeas, MD
  1. Yian Gu, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Adam M. Brickman, PhD,
    3. Scientific Advisory Boards:

    1. Currently serve on the scientific advisory board of Keystone Heart and ProPhase.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial board member of The Journal of the International Neuropsychological Society. Editorial board member of Neuropsychology Review

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant for ProPhase. Years: 2007-2011 and 2013-present. Consultant for Keystone Heart. Years: 2012-Present.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. grant support: NIH AG029949 PI 2007-2012 NIH AG024708 PI 2004-2006 NIH AG034189 PI 2010-2015 NIH AG043337 PI 2012-2014

    Research Support, Academic Entities:

    1. grant support: Columbia University PI 2008-2009 Columbia University PI 2012-2013

    Research Support, Foundations and Societies:

    1. grant support: Alzheimer's Association PI 2005-2007 Alzheimer's Association PI 2010-2012 Mary E. Groff Surgical Medical Research and Education Charitable Trust PI 2012-2013

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Yaakov Stern, PhD,
    4. Scientific Advisory Boards:

    1. Delirium Program Project Scientific Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 2012: (1) Toronto, Canada, Rotman Institute, Annual Baycrest Research Division Conference, Reimbursement;(2) Newark, NJ, Janssen, LLC and Pfizer Alzheimer's Disease Progression Monitoring Advisory Board Meeting, Honorarium; (3) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (4) Boston, Janssen, Global Advisory Committee Meeting for INROADS study, Reimbursement and Honorarium; (5) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; 2013: (6) Nashville, TN, ADCS, Advisory Board Meeting, Reimbursement; (7) , Hawaii, INS, Annual INS Mtg, Honorarium; (8) Florence, Italy, Accera, Inc./NYU,AD PD meeting, Reimbursement; (9) San Diego, CA,ADC, Directors' Meeting, Reimbursement; (10) (11) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (12) Chicago, AbbVie, Advisory Board Meeting, Honorarium; (13) Boston, MA, AAIC Annual Meeting, reimbursement; (14) Turin, Italy, Int'l Association of Logopedics and Phoniatrics, 29th World Congress of the IALP honorarium; (15) Toronto, Canada, MaRS Health and Digital Media Workshop, Reimbursement; (16) Chicago, Takeda Global Research & Development Center, Inc., Adjudication Kick-off Meeting, Honorarium; (17) Milan, Italy, UNIVERSIT? DEGLI STUDI DI MILANO, CATTEDRA DI NEUROLOGIA, 8th Conference of Neurology: Cognitive Reserve in Aging and Alzheimer's Disease, reimbursement; (18) Tel Aviv, Israel, University of Tel Aviv, Annual Brainstorming of AD, reimbursement; (19) Boston, MA, Eli Lilly, Measuring Function in Alzheimer?s Disease Working Group, Honorarium; 2014: (21) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (22) Barcelona, Spain, International Debate on Ageing and mental health, reimbursement; (23) Chicago, AAAS, Symposium: The Science of Resilient Aging, reimbursement; (24) Washington, D.C., IOM, Workshop on Cognitive Aging, reimbursement; (25) Philadelphia, ADNI, Steering Committee Meeting, reimbursement; (26) Boston, MA, Delirium PPG SAB-Planning of 2014, Reimbursement; (27) Copenhagen, Denmark, AAIC Annual Meeting, AIC and Lilly Symposium, Honorarium;(28) Philadelphia, Eli Lilly, Honorarium; (29) Boston, Delta Quest Foundation, Honorarium; 2015, (30) Dallas, TX, Eli Lilly, Working Group Mtg, Honorarium (31) Dallas, TX, Eli Lilly Primary Outcome Mtg, Honorarium;

    Editorial Boards:

    1. 1) Journal of the International Neuropsychological Society, Associate Editor, 1999-2013, Editorial Board 2013- present, 2)Cognitive and Behavioral Neurology, Editorial Board, 2005-present, 3)Neuropsychology, Editorial Board, 2006-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Allergan, (2) Cephalon, (3) Elan, (4) Eisai, (5) Pfizer, (6) Ortho-McNeil Neurologics, (7) Merck &Co, (8) Glaxo Smith Kline, (9) Ely Lily, (10) Janssen Alzheimer Immunotherapy (11) AbbVie Inc. (12) Takeda Global Research & Development Center Inc. (13) Piramal Imaging SA

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Piramal, (2) Forest Pharmeceutical

    Research Support, Government Entities:

    1. (1) NIH/NIA, R01AG034178, PI, 2009-2014. (2) NIH/NIA, 5R01AG007370-24, PI, 1989-2011. (3) NIH/NIA, (4) NIH/NIA, R01AG037212-05, Co-I, 2010-2015. (5) NIH/NIA, P50 AG08702- 25, Co-I, 1997-2015. (6) NIH/NIA, R01AG038465-04, PI, 2011- 2016. (7) NIH/NIA, R01AG033546-05, PI 2010-2015. (8) NIH/NIA, R01AG026158-09, PI, 2004-2016. (9) NIH/NINDS, R01NS070600-03, Co-I, 2010-2015. (10) NIH/NIA, R37NS029993- 21, Co-I, 2013-2015. (11) NIH, R01AG036469-03, Co-I, 2011- 16. (12) NIH, R01AG041795-01A1, Co-I, 2013-2018. (13) NIA, R01AG043463, Co-I, 2012-2017.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Alzheimer's Drug Development Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. (1) The Dependence Scale measures is licensed for use by commercial entities by Columbia University, and I receive funds from these licenses.

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Christian G. Habeck, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. R01AG038465 Stern (PI) 09/01/11 ? 08/31/16 Exploring Cognitive Aging Ability Using Reference Ability Networks The proposed research program constitutes a major reevaluation of the methods and goals of the study of cognitive aging that should provide major new, integrative, and perhaps simplifying, insights into the neural basis of the most important and central features of cognitive aging. Role: co-I R01AG033546 Stern (PI) 09/15/10 - 05/31/15 Exercise, aging, and cognition: Effect and mechanisms The goal of the proposed study is to extend the investigation of the beneficial effects of aerobic exercise to younger individuals, aged 25-40 and 50-65. Role: co-I R01 AG026158 Stern (PI) 09/15/04 - 08/31/16 Imaging of Cognition, Learning, and Memory in Aging This work will lead to better understanding of how aging and AD pathology impacts on the neural systems that mediate cognitive function and the neural mechanisms that differentiate successful and unsuccessful aging. In turn, it may provide clues for remediating or preventing age-related cognitive changes and delaying the onset of AD. Role: co-I R01NS076837 Cosentino (PI) 09/21/12 - 07/31/17 Examination of the Earliest Symptoms and Biomarkers of FTLD MAPT Carriers This project examines the earliest clinical symptoms of FTLD in carriers of a tau mutation. Role: co-I R01MH101172 Posner (PI) 09/01/11 ? 08/31/16 Imaging Stimulant Effects on Emotional Liability in Children with ADHD Role: co-I R21MH099388 Steinglass (PI) 01/13/14 ? 12/31/15 Multimodal imaging of the Mesocortical system in anorexia nervosa This project will use complementary neuroimaging techniques to study neural circuitry in anorexia nervosa. Using resting state functional neuroimaging, diffusion tensor imaging, and arterial spin labeling we will evaluate the mesocortical system in individuals with anorexia nervosa before and after weight restoration treatment, as compared with healthy controls. Role: co-I R01AG043463 Ochsner (PI) 09/01/12-8/31/17 Understanding cognitive mechanisms of emotion regulation in aging This project seeks to understand the ways in which the psychological and neural mechanisms underlying the cognitive regulation of emotion change in older adults. Role: co-I ADDF Gibson (PI) 01/01/15 ? 12/31/16 Benfortiamine in Alzheimer ?s Disease: A pilot Study This pilot study will test whether a vitamin B1 derivative that increases glucose utilization and diminishes AD symptoms in mouse models will be beneficial in patients with AD. Role: co-I R01AG043679 Gibson, Jordan (co-PIs) 09/01/14-05/31/19 Benfortiamine in Alzheimer ?s Disease: A pilot Study This pilot study will test whether a vitamin B1 derivative that increases glucose utilization and diminishes AD symptoms in mouse models will be beneficial in patients with AD. Role: co-I

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Qolamreza R. Razlighi, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. José A. Luchsinger, PhD,
    7. Scientific Advisory Boards:

    1. (1)Commercial: Nutricia, Inc

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Alzheimer's disease and associated disorders, editor in chief, 2015-Journal of Alzheimer's Disease, associate editor, 2008-

    Patents:

    1. NONE

    Publishing Royalties:

    1. Biessels GJ, Luchsinger JA. Diabetes and the Brain. Humana, Press 2009. Received $509.78 on 04/28/2010

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Agency: PCORI (Easygrant ID 7160) (J. Luchsinger), Title: Northern Manhattan Hispanic Caregiver intervention Effectiveness Study (NHiCE), Dates: 12/01/2013-11/30/2016, Goals: to compare the effectiveness of 2 dementia caregiver interventions, the New York University Caregiver Intervention, and the translation of the Resources for Enhancing Caregiver?s Health (REACH OUT) in a pragmatic randomized trial of 200 Hispanic relative caregivers of persons with dementia. Role: PI, Agency: NINR (1R01NR014430-01), Title: New York City Hispanic Dementia Caregiver Research Program (NHiRP), Principal investigator: Lucero; Luchsinger (contact); Mittelman, Dates: 06/01/13-05/31/18 Goals: to establish a program of research about Hispanic caregivers of persons with dementia. NHiRP will provide long term follow-up to an existing clinical trial, create a registry of caregivers, and develop an internet based intervention working with caregivers. Responsibilities: PI, Agency: NIDDK, Title: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE; 1U01DK098246). Principal Investigator: D. Nathan, J. Lachin, Dates: 12/01/12-07/31/20, Goals: GRADE is a multi-center randomized clinical trial to evaluate the relative long-term metabolic and clinical effects of four classes of drugs in combination with metformin for the treatment of type 2 diabetes. Responsibilities: PI of Cognitive Coordinating Center. Agency: NIMHD (P60 MD00206), Title: Northern Manhattan Center of Excellence in Minority Health and Health Disparities (NOCEMHD). Principal investigator: J. Luchsinger, Dates: 05/01/09-01/31/15, Goals: this center grant has 3 projects related to minority health including a prospective study of cognition in persons with diabetes, and 2 trials of community participatory research in diabetes and hypertension. Responsibilities: Center director, Agency: NIDDK (2U01DK048404), Title: DPPOS Neurocognitive Reading Center Principal Investigator: J. Luchsinger, Dates: 07/01/09-01/31/15, Goals: Coordinate the administration of neurocognitive assessments in the 26 sites of the Diabetes Prevention Program Outcomes Study (DPPOS) including traning and quality control. This grant is a subcontract to the St. Luke?s Roosevelt Hospital Center DPPOS site (PI: X. P-Sunyer). Responsibilities: principal investigator. Agency: NIMHD (3P60MD000206-09S2), Title: Bioethics in the Northern Manhattan Center of Excellence in Minority Health and Health Disparities (NOCEMHD) Principal investigator: J. Luchsinger. Dates: 09/22/2011-01/31/15, Goals: The goal is to conduct a 1-year bioethics program to address unresolved bioethics issue in minority health research. Responsibilities: principal investigator, Agency: NIMHD (3P60MD000206-09S1), Title: Environmental health disparities in NOCEMHD, Dates: 09/22/2011-01/31/2015 Principal investigator: J. Luchsinger. Goals: This application established the Contextual Health Disparities-Core (COHD) in the Northern Manhattan Center of Excellence in Minority Health and Health Disparities at Columbia University (NOCEMHD) Responsibilities: principal investigator. Agency: NIA (1R01AG037212-01), Title: Epidemiology of Biomarkers of Risk and Progression in Late Onset Alzheimer's Disease. Dates: 04/01/10-03/31/15, Principal Investigator: R. Mayeux, N.Schupf. Goals: To investigate biomarkers that predict Alzheimer?s disease risk. Responsibilities: co-investigator. Agency: NIA (R01AG034189), Title: White Matter Hyperintensities in aging and dementia. Dates: 3/15/10-2/28/15), Principal investigator: A. Brickman. Goals: to investigate the role of white matter hyperintensities ascertained on MRI in cognitive aging. Responsibilities: co-investigator. Agency: NIMH (R01 MH104574-01). Title: Peer-led healthy lifestyle program in supportive housing, Dates: 7/14/14-06/13/19. Principal Investigator: L. Cabassa. Goals: to carry out a clinical trial of a weight loss intervention among persons with severe mental illness. Responsibilities: co-investigator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Institute for the Study of Aging:

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Jennifer J. Manly, PhD,
    8. Scientific Advisory Boards:

    1. Reimbursement of travel costs associated with serving on the Medical and Scientific Advisory Board of the Alzheimer's Association

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel costs as a speaker at AAIC, Vancouver 2012, Alzheimer's Association (non-profit)

    Editorial Boards:

    1. Journal of the International Neuropsychological Society, associate editor, 2005 - 2014

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. National Academies of Medicine - 2014

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) National Institute on Aging, R01 AG028786, Role: Principal Investigator, 09/15/07 ? 06/30/13 (NCE) 2) National Institute on Aging, R01 AG037212, Role: Co-Investigator, 05/01/10 - 04/30/15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 2) Alzheimer?s Association, IIRG-11-202789, Role: Principal Investigator, 08/15/11 ? 08/14/14

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Nicole Schupf, PhD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. New York Methodist Hospital, Honorarium

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Janssen Alzheimer Immunology R&D LLC

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. AAIC: Down syndrome Professional Interest Group Executive Committee

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. support from NIH #P01HD035897(Co-I), (2010 - 2015) NIH #R01AG037212 (Co-PI), (2010-2015) NIH #U01 AG023749 (Co-PI),(2014 - 2019) NIH #P50 AG08702 (Co-I), (2010-2015) NIH #R01AG036040 (Co-I), (2009-2014) NIH #AG034189 (Co-I) (2010-2015) NIH #R01 DE022658 (Co-I) (2013-2016) ADDF (Co-I) ( 2015-2016) NIH R01 AGO43679 (2014-2019)

    Research Support, Academic Entities:

    1. NYS Institute for Basic Research in Developmental Disabilities

    Research Support, Foundations and Societies:

    1. Alzheimer Association IIRG-11-20279 (Co-I) 2012-2015

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Richard Mayeux, MD and
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. RO1 AG037212 Epidemiology of Biomarkers of Risk and Progression in Late onset Alzheimer?s Disease. Principal Investigator

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Nikolaos Scarmeas, MD
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Federal NIA grant AG028506

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Alzheimer?s Association grant IIRG-04-1353

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From The Taub Institute for Research in Alzheimer's Disease and the Aging Brain (Y.G., A.M.B., Y.S., C.G.H., O.R.R., J.A.L., J.J.M., N. Schupf, R.M., N. Scarmeas), The Gertrude H. Sergievsky Center (A.M.B., Y.S., C.G.H., J.A.L., J.J.M., N. Schupf, R.M., N. Scarmeas), the Department of Neurology (Y.G., A.M.B., Y.S., C.G.H., J.J.M., R.M.), the Department of Medicine (J.A.L.), and the Division of Epidemiology, Joseph P. Mailman School of Public Health (J.A.L., N. Schupf), Columbia University, New York, NY; and the National and Kapodistrian University of Athens Medical School (N. Scarmeas), Greece.
  1. Correspondence to Dr. Gu: yg2121{at}columbia.edu
View Full Text

Article usage

Article usage: October 2015 to July 2019

AbstractFullPdfSource
Oct 201583000141Highwire
Nov 20155040144135Highwire
Dec 2015131810244Highwire
Jan 201610574140Highwire
Feb 20166432325Highwire
Mar 20165552320Highwire
Apr 201644869Highwire
May 201652599Highwire
Jun 20164111112Highwire
Jul 201639873Highwire
Aug 201623811Highwire
Sep 201628833Highwire
Oct 201624977Highwire
Nov 2016343104Highwire
Nov 2016085pmc
Dec 201620442Highwire
Dec 201602510pmc
Jan 201752195Highwire
Jan 201707735pmc
Feb 201733744Highwire
Feb 201706626pmc
Mar 2017253426Highwire
Mar 201708221pmc
Apr 201721324Highwire
Apr 2017224146pmc
May 201718464Highwire
May 2017214138pmc
Jun 201722193Highwire
Jun 2017243941pmc
Jul 201715325Highwire
Jul 2017112939pmc
Aug 201721911Highwire
Aug 201792125pmc
Sep 201718812Highwire
Sep 2017253952pmc
Oct 201721503Highwire
Oct 2017244354pmc
Nov 201723212Highwire
Nov 2017215154pmc
Dec 201713923Highwire
Jan 201893391Highwire
Feb 2018183124Highwire
Mar 201817085Highwire
Apr 201817264Highwire
Apr 2018126682pmc
May 2018245105Highwire
Jun 201825257Highwire
Jun 2018132931pmc
Jul 201817835Highwire
Aug 201816141Highwire
Aug 201882524pmc
Sep 201816453Highwire
Oct 201822137Highwire
Nov 201824750Highwire
Dec 201822921Highwire
Jan 201920732Highwire
Feb 201918321Highwire
Mar 201919880Highwire
Apr 201929092Highwire
May 201914433Highwire
Jun 201929058Highwire
Jul 201938831Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

More Online

CME Course

Topics Discussed

Alert Me